Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 123

Similar articles for PubMed (Select 23701262)

1.

GSK256073, a selective agonist of G-protein coupled receptor 109A (GPR109A) reduces serum glucose in subjects with type 2 diabetes mellitus.

Dobbins RL, Shearn SP, Byerly RL, Gao FF, Mahar KM, Napolitano A, Nachbaur GJ, Le Monnier de Gouville AC.

Diabetes Obes Metab. 2013 Nov;15(11):1013-21. doi: 10.1111/dom.12132. Epub 2013 Jun 12.

PMID:
23701262
2.

GSK256073 acutely regulates NEFA levels via HCA2 agonism but does not achieve durable glycaemic control in type 2 diabetes. A randomised trial.

Dobbins R, Byerly R, Gaddy R, Gao F, Mahar K, Napolitano A, Ambery P, Le Monnier de Gouville AC.

Eur J Pharmacol. 2015 May 15;755:95-101. doi: 10.1016/j.ejphar.2015.03.005. Epub 2015 Mar 13.

PMID:
25773496
3.

Gut hormone pharmacology of a novel GPR119 agonist (GSK1292263), metformin, and sitagliptin in type 2 diabetes mellitus: results from two randomized studies.

Nunez DJ, Bush MA, Collins DA, McMullen SL, Gillmor D, Apseloff G, Atiee G, Corsino L, Morrow L, Feldman PL.

PLoS One. 2014 Apr 3;9(4):e92494. doi: 10.1371/journal.pone.0092494. eCollection 2014.

5.

Acute and short-term administration of a sulfonylurea (gliclazide) increases pulsatile insulin secretion in type 2 diabetes.

Juhl CB, Pørksen N, Pincus SM, Hansen AP, Veldhuis JD, Schmitz O.

Diabetes. 2001 Aug;50(8):1778-84.

6.

Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin.

Kapitza C, Forst T, Coester HV, Poitiers F, Ruus P, Hincelin-Méry A.

Diabetes Obes Metab. 2013 Jul;15(7):642-9. doi: 10.1111/dom.12076. Epub 2013 Feb 25.

7.

Control of postprandial hyperglycemia: optimal use of short-acting insulin secretagogues.

Carroll MF, Izard A, Riboni K, Burge MR, Schade DS.

Diabetes Care. 2002 Dec;25(12):2147-52.

PMID:
12453952
8.
9.

Safety, tolerability, pharmacokinetics and pharmacodynamics of albiglutide, a long-acting GLP-1-receptor agonist, in Japanese subjects with type 2 diabetes mellitus.

Seino Y, Nakajima H, Miyahara H, Kurita T, Bush MA, Yang F, Stewart MW.

Curr Med Res Opin. 2009 Dec;25(12):3049-57. doi: 10.1185/03007990903372999.

PMID:
19863477
10.

Benfluorex in obese noninsulin dependent diabetes mellitus patients poorly controlled by insulin: a double blind study versus placebo.

Pontiroli AE, Pacchioni M, Piatti PM, Cassisa C, Camisasca R, Pozza G.

J Clin Endocrinol Metab. 1996 Oct;81(10):3727-32.

PMID:
8855830
11.

Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.

Bergman AJ, Stevens C, Zhou Y, Yi B, Laethem M, De Smet M, Snyder K, Hilliard D, Tanaka W, Zeng W, Tanen M, Wang AQ, Chen L, Winchell G, Davies MJ, Ramael S, Wagner JA, Herman GA.

Clin Ther. 2006 Jan;28(1):55-72.

PMID:
16490580
12.

The glucokinase activator AZD6370 decreases fasting and postprandial glucose in type 2 diabetes mellitus patients with effects influenced by dosing regimen and food.

Ericsson H, Sjöberg F, Heijer M, Dorani H, Johansson P, Wollbratt M, Norjavaara E.

Diabetes Res Clin Pract. 2012 Dec;98(3):436-44. doi: 10.1016/j.diabres.2012.09.025. Epub 2012 Sep 23.

PMID:
23010558
13.

Short-term comparison of once- versus twice-daily administration of glimepiride in patients with non-insulin-dependent diabetes mellitus.

Sonnenberg GE, Garg DC, Weidler DJ, Dixon RM, Jaber LA, Bowen AJ, DeChemey GS, Mullican WS, Stonesifer LD.

Ann Pharmacother. 1997 Jun;31(6):671-6.

PMID:
9184703
14.
15.

Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Troglitazone Study Group.

Kumar S, Boulton AJ, Beck-Nielsen H, Berthezene F, Muggeo M, Persson B, Spinas GA, Donoghue S, Lettis S, Stewart-Long P.

Diabetologia. 1996 Jun;39(6):701-9. Erratum in: Diabetologia 1996 Oct;39(10):1245.

PMID:
8781766
16.

Multiple mechanisms of GW-9508, a selective G protein-coupled receptor 40 agonist, in the regulation of glucose homeostasis and insulin sensitivity.

Ou HY, Wu HT, Hung HC, Yang YC, Wu JS, Chang CJ.

Am J Physiol Endocrinol Metab. 2013 Mar 15;304(6):E668-76. doi: 10.1152/ajpendo.00419.2012. Epub 2013 Jan 22.

17.

The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus.

Rosenblatt S, Miskin B, Glazer NB, Prince MJ, Robertson KE; Pioglitazone 026 Study Group.

Coron Artery Dis. 2001 Aug;12(5):413-23.

PMID:
11491207
18.

Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.

Sarashina A, Sesoko S, Nakashima M, Hayashi N, Taniguchi A, Horie Y, Graefe-Mody EU, Woerle HJ, Dugi KA.

Clin Ther. 2010 Jun;32(6):1188-204. doi: 10.1016/j.clinthera.2010.06.004.

PMID:
20637971
19.

Control of postprandial plasma glucose by an oral insulin product (HIM2) in patients with type 2 diabetes.

Kipnes M, Dandona P, Tripathy D, Still JG, Kosutic G.

Diabetes Care. 2003 Feb;26(2):421-6.

PMID:
12547873
20.

Pharmacokinetics and pharmacodynamics of exenatide extended-release after single and multiple dosing.

Fineman M, Flanagan S, Taylor K, Aisporna M, Shen LZ, Mace KF, Walsh B, Diamant M, Cirincione B, Kothare P, Li WI, MacConell L.

Clin Pharmacokinet. 2011 Jan;50(1):65-74. doi: 10.2165/11585880-000000000-00000.

PMID:
21142268
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk